Roche is a leader in the research and development of pharmaceutical and diagnostic solutions that look beyond today’s horizons and make a profound difference in people’s lives.
Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from resources of one of the world’s largest pharmaceutical companies.
Eisai Limited (pronounced ā-zī) is the Canadian pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd, manufacturers of FYCOMPA and BANZEL. Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide.
EMD Serono provides innovative drug therapies that address unmet medical needs in the areas of neurodegenerative diseases, fertility and endocrinology.
Grifols is a global pharmaceutical company that develops and produces plasma-derived therapies and manufactures hospital pharmacy products, intravenous solutions, diagnostic tools and medical devices.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care.
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential.
Abbvie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives.
Sunovion Pharmaceuticals Canada Inc. is focused on the commercialization of prescription products in Canada.
At UCB Canada Inc. we aspire to be the Patient-Centric global biopharmaceutical leader transforming the lives of people with severe diseases.
Athena Diagnostics is a leader in diagnostic testing for neurological diseases and offers innovative tests for Alzheimer’s disease, muscular dystrophy, and other neuromuscular and developmental disorders.
CNSF Virtual Exhibit Hall © 2017
The CNSF values the Platinum level support it has received from Hoffmann-La Roche for 2017, which includes the sponsorship of Congress lanyards, support of a Congress Section 1 co-developed session on “Changing the course of MS: high efficacy therapeutic options”, the purchase of 2 Exhibit booths, Neuro|News advertising and Section 1 co-developed programs across Canada for Neurologists and Nurses on MS.
The CNSF values the Gold Level support it has received from Sanofi Genzyme for 2017, which includes a Lunch 'n Learn on “The long term Implications of selecting an oral disease modifying therapy” (unaccredited), a “Pompe Medical Panel Discussion” (unaccredited), and the purchase of 2 Exhibit booths.
The CNSF values the Silver level support it has received from Eisai for 2017, which includes the purchase of an Exhibit booth, and Neuro|News advertising.
The CNSF values the Silver level support it has received from EMD Serono for 2017, which includes the support of the Congress MS Duels Program on Multiple Sclerosis (unaccredited) a booth purchase, sponsorship of the Empress Key cards and Congress Delegate Gift and Neuro|News advertising.
The CNSF values the Silver level support it has received from Grifols for 2017, which includes the support of the Neuromuscular Clinical Case Study, the purchase of a booth and a Fellowship Grant to CSCN for 2017/2018.
The CNSF values the Silver level support it has received from Novartis for 2017, which includes a Lunch n' Learn on Alzheimer’s and MS (unaccredited), the purchase of 2 Exhibit booths and support of the Congress Course Notes Program.
The CNSF values the Bronze level support it has received from Allergan for 2017, which includes the support of the “Update in Headache Medicine” Course